Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amzell Sees Benefit From High-Strength Topical Diclofenac

Diclofenac 3.06% Gel Shows Promise For Knee Osteoarthritis

Executive Summary

Amzell has revealed trial results indicating that its diclofenac 3.06% gel formulation is effective for treating knee osteoarthritis symptoms.

You may also be interested in...



Virpax And MedPharm Advance Diclofenac Spray

Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.

Amgen Sees Acceleration In US Biosimilars Market

The US marketplace for biosimilars is accelerating faster than the EU at a similar point in its existence, based on approval rates, Amgen has observed in a preview of its 2022 trends in biosimilars report that also offers new data on pricing and uptake.

Glenmark Bolsters US OTC Portfolio With Wockhardt Products

Glenmark has moved to bolster its over-the-counter business in the US by acquiring a portfolio of approved generic OTC products from Wockhardt.

Topics

Latest News
UsernamePublicRestriction

Register

GB150168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel